Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Empiric therapy with Carbapenem-sparing regimens for bloodstream infections due to extended-spectrum β-Lactamase–producing Enterobacteriaceae: results from the INCREMENT cohort

  • Palacios-Baena, Zaira R.
  • Gutiérrez-Gutiérrez, Belén
  • Calbo, Esther
  • Almirante, Benito
  • Viale, Pier-Luigy
  • Oliver, Antonio
  • Pintado, Vicente
  • Gasch Blasi, Oriol
  • Martínez-Martínez, Luis
  • Pitout, Johann
  • Akova, Murat
  • Peña, Carmen
  • Molina Gil-Bermejo, José
  • Lorenzo-Hernández, Alicia
  • Venditti, Mario
  • Prim, Nuria
  • Bou, Germán
  • Tacconelli, Evelina
  • Tumbarello, Maria
  • Hamprecht, Axel
  • Giamarellou, Helen
  • Almela, Manuel
  • Pérez, Federico J.
  • Schwaber, Mitchell J.
  • Bermejo, Joaquín
  • Lowman, Warren
  • Hsueh, Po-Ren
  • Paño-Pardo, José Ramón
  • Torre-Cisneros, Julián
  • Souli, Maria
  • Bonomo, Robert
  • Carmeli, Yehuda
  • Paterson, David L.
  • Pascual, Álvaro
  • Rodríguez-Baño, Jesús
[Abstract] Background: There is little information about the efficacy of active alternative drugs to carbapenems except β-lactam/β-lactamase inhibitors for the treatment of bloodstream infections (BSIs) due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E). The objective of this study was to assess the outcomes of patients with BSI due to ESBL-E who received empiric therapy with such drugs (other active drugs [OADs]) or carbapenems. Methods: A multinational retrospective cohort study of patients with BSI due to ESBL-E who received empiric treatment with OADs or carbapenems was performed. Cox regression including a propensity score for receiving OADs was performed to analyze 30-day all-cause mortality as main outcome. Clinical failure and length of stay were also analyzed. Results: Overall, 335 patients were included; 249 received empiric carbapenems and 86 OADs. The most frequent OADs were aminoglycosides (43 patients) and fluoroquinolones (20 patients). Empiric therapy with OADs was not associated with mortality (hazard ratio [HR], 0.75; 95% confidence interval [CI], .38-1.48) in the Cox regression analysis. Propensity score-matched pairs, subgroups, and sensitivity analyses did not show different trends; specifically, the adjusted HR for aminoglycosides was 1.05 (95% CI, .51-2.16). OADs were neither associated with 14-day clinical failure (adjusted odds ratio, 0.62; 95% CI, .29-1.36) nor length of hospital stay. Conclusions: We were unable to show that empiric treatment with OAD was associated with a worse outcome compared with carbapenems. This information allows more options to be considered for empiric therapy, at least for some patients, depending on local susceptibility patterns of ESBL-E., The study was funded by the Ministerio de Economía y Competitividad-Instituto de Salud Carlos III through the following grants: Acción Estratégica en Salud (PI10/02021 and PI14/01832), and Plan Nacional de I+D+i, Subdirección General de Redes y Centros de Investigación Cooperativa, Spanish Network for Research in Infectious Diseases (REIPI RD 12/0015/0010 and RD16/0016/0001), co-financed by the European Development Regional Fund “A way to achieve Europe,” Operative Programme Intelligent Growth 2014–2020. B. G. G., J. R. B., A. P. H., and Y. C. also received funds from the Innovative Medicines Initiative, the European Union’s Seventh Framework Programme (FP7/2007–2013), and in-kind contributions from European Federation of Pharmaceutical Industries and Associations companies (COMBACTE-CARE project, agreement 115620). R. A. B. was also supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program and the Geriatric Research Education and Clinical Center VISN 10 (VISN 10 GRECC), and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under award numbers R01AI072219 and R01AI063517.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae

  • Palacios-Baena, Zaira R.
  • Gutiérrez-Gutiérrez, Belén
  • Cueto-López, Marina
  • Viale, Pier-Luigy
  • Venditti, Mario
  • Hernández-Torres, Alicia
  • Oliver, Antonio
  • Martínez-Martínez, Luis
  • Calbo, Esther
  • Pintado, Vicente
  • Gasch Blasi, Oriol
  • Almirante, Benito
  • Lepe, José Antonio
  • Pitout, Johann
  • Akova, Murat
  • Peña-Miralles, Carmen
  • Schwaber, Mitchell J.
  • Tumbarello, Maria
  • Tacconelli, Evelina
  • Origüen, Julia
  • Prim, Nuria
  • Bou, Germán
  • Giamarellou, Helen
  • Bermejo, Joaquín
  • Hamprecht, Axel
  • Pérez, Federico J.
  • Almela, Manuel
  • Lowman, Warren
  • Hsueh, Po-Ren
  • Navarro-San Francisco, Carolina
  • Torre-Cisneros, Julián
  • Carmeli, Yehuda
  • Bonomo, Robert
  • Paterson, David L.
  • Pascual, Álvaro
  • Rodríguez-Baño, Jesús
[Abstract] Background: Bloodstream infections (BSIs) due to ESBL-producing Enterobacteriaceae (ESBL-E) are frequent yet outcome prediction rules for clinical use have not been developed. The objective was to define and validate a predictive risk score for 30 day mortality. Methods: A multinational retrospective cohort study including consecutive episodes of BSI due to ESBL-E was performed; cases were randomly assigned to a derivation cohort (DC) or a validation cohort (VC). The main outcome variable was all-cause 30 day mortality. A predictive score was developed using logistic regression coefficients for the DC, then tested in the VC. Results: The DC and VC included 622 and 328 episodes, respectively. The final multivariate logistic regression model for mortality in the DC included age >50 years (OR = 2.63; 95% CI: 1.18-5.85; 3 points), infection due to Klebsiella spp. (OR = 2.08; 95% CI: 1.21-3.58; 2 points), source other than urinary tract (OR = 3.6; 95% CI: 2.02-6.44; 3 points), fatal underlying disease (OR = 3.91; 95% CI: 2.24-6.80; 4 points), Pitt score >3 (OR = 3.04; 95 CI: 1.69-5.47; 3 points), severe sepsis or septic shock at presentation (OR = 4.8; 95% CI: 2.72-8.46; 4 points) and inappropriate early targeted therapy (OR = 2.47; 95% CI: 1.58-4.63; 2 points). The score showed an area under the receiver operating curve (AUROC) of 0.85 in the DC and 0.82 in the VC. Mortality rates for patients with scores of < 11 and ≥11 were 5.6% and 45.9%, respectively, in the DC, and 5.4% and 34.8% in the VC. Conclusions: We developed and validated an easy-to-collect predictive scoring model for all-cause 30 day mortality useful for identifying patients at high and low risk of mortality., This study was funded by: the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III co-financed by the European Development Regional Fund ‘A way to achieve Europe’ ERDF, the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), FIS grant PI10/02021 and FIS grant PI14/01832. B. G. G., J. R. B., A. P. and Y. C. also received funds from the COMBACTE-CARE project, Innovative Medicines Initiative (IMI), the European Union’s Seventh Framework Programme (FP7/2007-2013) and in-kind contributions from EFPIA companies. R. A. B. was also supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program and the Geriatric Research Education and Clinical Center VISN 10 (VISN 10 GRECC), and the NIAID of the NIH under award numbers R01AI072219 and R01AI063517.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Meropenem heteroresistance in clinical isolates of OXA-48–producing Klebsiella pneumoniae

  • López-Camacho, E.
  • Paño-Pardo, J.R.
  • Sotillo, A.
  • Elías-López, C.
  • Martínez-Martínez, L.
  • Gómez-Gil, R.
  • Mingorance, J.
OXA-48–producing Klebsiella pneumoniae isolates often show growth of colonies within inhibition zones in carbapenem diffusion assays. The nature of these colonies was investigated in a series of clinical isolates of OXA-48–producing K. pneumoniae obtained in the context of a hospital outbreak, and they were found to be persistent colonies that reproduced again the same phenotype when they were collected and tested in diffusion assays again. The frequency of mutations conferring resistance to meropenem (8 µg/mL) was determined for the same isolates. The average mutation frequency was 5.47·10-6 (range: 2.59·10-8–5.87·10-5), and the analysis of several resistant mutants showed that all of them had mutations in the ompK36 porin gene. Heteroresistance was investigated using population analysis profiling. The profiles were compatible with mutation frequency assays, and all the colonies analyzed were resistant mutants. In OXA-48–producing K. pneumoniae, the growth of persisters seems to be specific of diffusion assays.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Proof-of-concept trial of the combination of lactitol with Bifidobacterium bifidum and Lactobacillus acidophilus for the eradication of intestinal OXA-48-producing Enterobacteriaceae

  • Ramos-Ramos, J.C.
  • Lázaro-Perona, F.
  • Arribas, J.R.
  • García-Rodríguez, J.
  • Mingorance, J.
  • Ruiz-Carrascoso, G.
  • Borobia, A.M.
  • Paño-Pardo, J.R.
  • Herruzo, R.
  • Arnalich, F.
Background: The major reservoir of carbapenemase-producing Enterobacteriaceae (CPE) is the gastrointestinal tract of colonized patients. Colonization is silent and may last for months, but the risk of infection by CPE in colonized patients is significant. Methods: Eight long-Term intestinal carriers of OXA-48-producing Enterobacteriaceae (OXA-PE) were treated during 3 weeks with daily oral lactitol (Emportal®), Bifidobacterium bifidum and Lactobacillus acidophilus (Infloran®). Weekly stool samples were collected during the treatment period and 6 weeks later. The presence of OXA-PE was investigated by microbiological cultures and qPCR. Results: At the end of treatment (EoT, secondary endpoint 1), four of the subjects had negative OXA-PE cultures. Three weeks later (secondary endpoint 2), six subjects were negative. Six weeks after the EoT (primary endpoint), three subjects had negative OXA-PE cultures. The relative intestinal load of OXA-PE decreased in all the patients during treatment. Conclusions: The combination of prebiotics and probiotics was well tolerated. A rapid reduction on the OXA-PE intestinal loads was observed. At the EoT, decolonization was achieved in three patients.